Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBIT Margin: 2021-2024

Historic EBIT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to -10.78%.

  • Kiniksa Pharmaceuticals International's EBIT Margin rose 2189.00% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 1321.00%. This contributed to the annual value of -10.78% for FY2024, which is 145.00% down from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's EBIT Margin is -10.78%, which was down 15.61% from -9.32% recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year EBIT Margin high stood at 97.73% for FY2022, and its period low was -406.38% during FY2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median EBIT Margin value was -9.32% (recorded in 2023), while the average stood at 25.88%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBIT Margin spiked by 50,411bps in 2022, and later tumbled by 10,705bps in 2023.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's EBIT Margin stood at -406.38% in 2021, then soared by 50,411bps to 97.73% in 2022, then crashed by 10,705bps to -9.32% in 2023, then tumbled by 145bps to -10.78% in 2024.